Collection 

Antifungals and Resistance

Submission status
Open
Submission deadline

The Fungal Kingdom includes a phenomenal diversity of organisms, some of which pose devastating threats to agriculture, human health, and biodiversity. There is a limited number of antifungal agents, and the emergence of resistance threatens the efficacy of existing antifungals. There is an urgent need for new strategies to thwart emerging and resistant fungal pathogens alongside the need for greater understanding of one-health aspects. This collection aims to publish cutting-edge research on methods to mitigate fungal infections  and to combat the emergence of resistance. 

Diverse topics will be covered, including:

  • Current antifungals used in medicine, agriculture, and animal husbandry
  • Mechanisms enabling the evolution of resistance to antifungal agents
  • Emergence of resistance to antifungals in the environment and the clinic
  • Reservoirs of antifungal resistance
  • Effects of antifungals on microbiomes
  • Microbiomes as sources of new antifungals
  • Approaches for discovery of new antifungals
  • Identifying targets of new antifungals
  • Antifungal combinations and synergy
  • Antifungal stewardship
  • Policy aspects of antifungal development and usage

This Collection supports and amplifies research related to SDG 3.

Submit manuscript
Manuscript editing services
Microscopic image of growing molds or mold fungus and spores

Editors

  • Matthew Fisher  &

    Matthew Fisher

    Professor of Fungal Disease Epidemiology, Faculty of Medicine, School of Public Health, Imperial College London, UK

  • Leah Cowen

    Leah Cowen

    University of Toronto Toronto, ON, Canada

Prof. Matthew Fisher works on pathogenic fungi, microbiomes and antimicrobial resistance, and heads a research group in the MRC Centre for Global Infectious Disease Analysis in the Imperial College London School of Public Health. His research group is focused on developing genomic epidemiology and experimental models to uncover the factors driving fungal infections in order to develop new methods of diagnosis, surveillance and control. He researches ‘One Health’ aspects of the microbe-environment-human interface and co-Directs the Georgina Mace Centre for the Living Planet.

 

Dr. Leah Cowen is Vice-President, Research and Innovation, and Strategic Initiatives at the University of Toronto, Professor in the Department of Molecular Genetics, co-Director of the CIFAR Fungal Kingdom: Threats & Opportunities program, and co-Founder and Chief Scientific Officer of Bright Angel Therapeutics, a company focused on development of novel antifungals. She has received a Burroughs Wellcome Fund Career Award, Grand Challenges Canada Star in Global Health Award, E.W.R. Steacie Award, and Canada Research Chair in Microbial Genomics & Infectious Disease. She is an elected Fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Her laboratory takes an interdisciplinary approach to understand how fungi cause human disease and evolve resistance to antifungal drugs, leveraging fundamental biological insights to advance development of new strategies to treat life-threatening fungal, infectious disease.